Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ER Y537S
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ER mutation (18)
ER D538G (11)
ESR1 mutation (9)
ER positive + ESR1 mutation (6)
ER Y537N (5)
ER negative + PIK3CA H1047R (2)
PIK3CA mutation + ESR1 mutation (2)
ER D538G + ER F404L (1)
ER E380Q (1)
ER E380Q + ER F404L (1)
ER F404L (1)
ER L536Q (1)
ER T594T (1)
ER Y537C (1)
ER rs2234693 (1)
ESR1 rs1801132 (1)
ESR1 rs2228480 (1)
ESR1 rs2234693T>C (1)
ESR1 rs9322354 (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA mutation + ER mutation (1)
ER mutation (18)
ER D538G (11)
ESR1 mutation (9)
ER positive + ESR1 mutation (6)
ER Y537N (5)
ER negative + PIK3CA H1047R (2)
PIK3CA mutation + ESR1 mutation (2)
ER D538G + ER F404L (1)
ER E380Q (1)
ER E380Q + ER F404L (1)
ER F404L (1)
ER L536Q (1)
ER T594T (1)
ER Y537C (1)
ER rs2234693 (1)
ESR1 rs1801132 (1)
ESR1 rs2228480 (1)
ESR1 rs2234693T>C (1)
ESR1 rs9322354 (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA mutation + ER mutation (1)
›
Associations
(17)
News
Trials
Search handles
@LGerratana
Search handles
@LGerratana
Filter by
Latest
1year
New data supporting a deeper #ESR1 variant characterization in #BreastCancer. Y537S is resistant to #SERD #SERM due to stable conformation and activity. L536 shows varying sensitivity, greatest resistance: AZD9833 GDC-0810 RAD1901 #PrecisionMedicine #bcsm https://t.co/5llI1gngbs (@LGerratana)
1 year ago
ER (Estrogen receptor)
|
ER Y537S
|
Orserdu (elacestrant) • camizestrant (AZD9833) • brilanestrant (GDC-0810)
almost2years
If you have ER+ metastatic breast cancer with an ESR1 mutation Y537S, @CancerCenter this phase I/2 trial offers a new oral selective estrogen receptor covalent antagonist (no more than 1 prior line of chemo) https://t.co/dTCNw4Cl3w. @ErikaHamilton9 (@eugeneahn)
almost 2 years ago
ER (Estrogen receptor)
|
ER mutation • ER Y537S • ESR1 mutation
almost3years
In the phase 2, stable disease was seen in 43% of people and a partial response in 17%. Those with the Y537S ESR1 mutation had the highest clinical benefit rate, although those with D538G also showed some benefit. #ASCO21 #bcsm (@stage4kelly)
almost 3 years ago
Clinical • P2 data
|
ER (Estrogen receptor)
|
ER mutation • ER Y537S • ER D538G
over3years
H3B-6545はESR1 Y537S変異やCDK4/6阻害薬・フルベストラントを含む治療歴の多いER+HER2-転移乳癌に対し有望【SABCS2020】:がんナビ サンアントニオ乳がんシンポジウムからのニュースです。今後の開発に期待します。 #乳がん #SABCS20 https://t.co/2VkXfo0c3i (@cancer_navi)
over 3 years ago
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
|
ER Y537S
|
H3B-6545
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login